1. Scrip
  2. >>Archive

Cangene names James Sedor CEO

 
• By Gemma Sharman

Cangene Corporation, a biopharmaceutical company focused on speciality plasma products, has appointed John Sedor president and chief executive officer, and a member of the board of directors. Mr Sedor will join Cangene on 12 September, taking over from chief financial officer Michael Graham, who has been serving as interim CEO. Mr Sedor most recently served as president, CEO and director of CPEX Pharmaceuticals.

Cangene Corporation, a biopharmaceutical company focused on speciality plasma products, has appointed John Sedor president and chief executive officer, and a member of the board of directors. Mr Sedor will join Cangene on 12 September, taking over from chief financial officer Michael Graham, who has been serving as interim CEO. Mr Sedor most recently served as president, CEO and director of CPEX Pharmaceuticals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.